Elucid

Executive Summary

Elucid is a Boston-based medical technology company developing AI-powered software for non-invasive cardiovascular plaque analysis. Its flagship product, PlaqueIQ, is FDA-cleared and uses CT angiography scans to quantify and characterize arterial plaque composition, validated against ground-truth histology. The company's platform addresses a critical gap in cardiovascular care by providing physicians with detailed, lesion-level plaque data to enable personalized treatment pathways for atherosclerosis. Founded in 2013, Elucid operates at the intersection of cardiovascular diagnostics, AI, and machine learning, targeting a large and growing market as cardiovascular disease remains the leading cause of death globally. The company's proprietary algorithms have the potential to improve risk stratification and guide therapeutic decisions, offering a differentiated approach compared to traditional imaging methods that rely on stenosis severity alone. Elucid's technology is well-positioned for adoption given the increasing use of CT angiography in clinical practice and the push for precision medicine. The company's AI-driven insights could reduce unnecessary interventions and optimize patient outcomes. While specific financial details and funding history are not publicly available, Elucid's FDA clearance and validation against histology provide a strong foundation for commercialization. Key challenges include competition from other AI-based imaging analysis tools and the need to demonstrate cost-effectiveness and clinical utility in large-scale studies. Overall, Elucid represents a compelling opportunity in the AI diagnostics space, with potential for significant impact on cardiovascular disease management.

Upcoming Catalysts (preview)

• Q3 2026Publication of landmark clinical validation study demonstrating PlaqueIQ's impact on treatment decisions80% success
• Q4 2026Strategic partnership with a major imaging equipment manufacturer for distribution50% success
• H1 2027Expansion of FDA clearance to include plaque vulnerability assessment for stroke risk60% success